DrugDashboards

Hydrocodone Bitartrate

Hydrocodone Bitartrate · HYDROCODONE BITARTRATE 20 mg/1 · Capsule, Extended Release · Oral · Alvogen Inc.

NDC 47781-0411-60 · 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price is down 13% over the past year, to $6.87 per unit. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$6.87per EAinvoice-surveyed acquisition cost · Feb 19, 2025
  • Part D plans paid (avg)$9.23per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$9.58per unitnegotiated price across 107 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$9.58per unit
middle half $7.81$9.65 · 107 plans · Apr 1, 2026
Est. net of rebates
≈ $9.58
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
2%of plans cover it
tier 4 · prior auth 64% · step therapy 0% · qty limit 80%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$5.00$10.00Apr 2024Feb 2025$6.87
9 price points · per EA · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

#30 count
$206.24
#90 count
$618.73

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2024)

$30,806
73 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for hydrocodone bitartrate (oral solid) in the next 90 days

sole-source market · price up 9% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 4 across plans
  • Costs ≥ $950/fill · avg $557.50 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · Opioid Analgesic REMS Shared System REMS

Regulatory

Application
ANDA206986
TE code
Approval date
Jan 21, 2020
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Hydrocodone Bitartrate (Capsule, Extended Release)

LabelerStrengthFirst seenLast seen
Alvogen Inc.HYDROCODONE BITARTRATE 10 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.HYDROCODONE BITARTRATE 15 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.HYDROCODONE BITARTRATE 20 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.HYDROCODONE BITARTRATE 30 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.HYDROCODONE BITARTRATE 40 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.HYDROCODONE BITARTRATE 50 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Hydrocodone Bitartrate — NDC 47781-0411-60," retrieved September 3, 2026, https://drugdashboards.com/drug/47781041160.

Free to cite with attribution — see how the data is put together.